Computational oncology — mathematical modelling of drug regimens for precision medicine

@article{Barbolosi2016ComputationalO,
  title={Computational oncology — mathematical modelling of drug regimens for precision medicine},
  author={Dominique Barbolosi and Joseph Ciccolini and Bruno Lacarelle and Fabrice Barlesi and Nicolas Andr{\'e}},
  journal={Nature Reviews Clinical Oncology},
  year={2016},
  volume={13},
  pages={242-254}
}
Computational oncology is a generic term that encompasses any form of computer-based modelling relating to tumour biology and cancer therapy. Mathematical modelling can be used to probe the pharmacokinetics and pharmacodynamics relationships of the available anticancer agents in order to improve treatment. As a result of the ever-growing numbers of druggable molecular targets and possible drug combinations, obtaining an optimal toxicity–efficacy balance is an increasingly complex task… Expand
Precision Medicine with Imprecise Therapy: Computational Modeling for Chemotherapy in Breast Cancer1
TLDR
It is posited that mathematical models can improve the application of anticancer therapeutics in the era of precision medicine and is compared to chemotherapy to radiation therapy. Expand
Towards rational cancer therapeutics: optimizing dosing, delivery, scheduling and combinations.
TLDR
The current knowledge regarding PK/PD relationships of anticancer agents, from decades-old cytotoxics to the latest immune checkpoint inhibitors, the most frequent sources for long-neglected inter-patient variability impacting on drug exposure levels, and what could be done to achieve real personalized medicine in oncology are covered. Expand
Role of Clinical Pharmacokinetics Studies in Contemporary Oncology Drug Development
  • F. Uckun, S. Qazi
  • Medicine
  • Drug Discovery and Evaluation: Methods in Clinical Pharmacology
  • 2018
Pharmacokinetics (PK) studies enable drug developers to elucidate the relationship of dose to blood concentrations of drugs in various patient populations and determining the need for dose adjustmentExpand
Pharmacodynamic Therapeutic Drug Monitoring for Cancer: Challenges, Advances, and Future Opportunities.
TLDR
This review focuses on discussing some of the challenges faced to date in translating preclinical pharmacodynamic biomarker approaches to a clinical setting, and selected examples of anticancer drugs where there is existing evidence to potentially advance pharmacodynamic therapeutic drug monitoring approaches to deliver more effective treatment. Expand
Towards personalized computational oncology: from spatial models of tumour spheroids, to organoids, to tissues
TLDR
This review is a survey of mathematical models that explicitly take into account the spatial architecture of three-dimensional tumours and address tumour development, progression and response to treatments and discusses models of epithelial acini, multicellular spheroids, normal and tumourSpheroids and organoids, and multi-component tissues. Expand
Prospect for application of mathematical models in combination cancer treatments
The long-term efficacy of targeted therapeutics for cancer treatment can be significantly limited by the type of therapy and development of drug resistance, inter alia. Experimental studies indicateExpand
Pharmacokinetic/pharmacodynamic modeling of combination-chemotherapy for lung cancer.
TLDR
A framework for systematic evaluation of tumor response to combination chemotherapy is established, with results with the chosen parameter set indicate that although a metronomic regimen may provide advantage over MTD, the combination of these regimens may not necessarily offer improved response. Expand
Optimizing drug development in oncology by clinical trial simulation: Why and how?
TLDR
While recognizing that CTS can never replace 'real-life' trials, they should be implemented in future drug development schemes to provide quantitative support for decision-making. Expand
The future of cancer treatments: a critical review of mathematical models for combination cancer therapy
The long-term efficacy of targeted therapeutics for cancer treatment can be significantly limited by the type of therapy and development of drug resistance, inter alia. Experimental studies indicateExpand
Mechanistic models for hematological toxicities: Small is beautiful
TLDR
Developing mathematical models to describe pharmacodynamic end points with anticancer drugs is a rising strategy in precision medicine in oncology and calls for using primarily topdown approaches, such as compartmental analysis, before developing pharmacokinetics/pharmacodynamics (PK/PD) models likely to help oncologists determine the optimal dosing and scheduling of a given drug to a given patient. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 120 REFERENCES
Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs
Over the last 10 years, proofs of the clinical interest of therapeutic drug monitoring (TDM) of certain anticancer drugs have been established. Numerous studies have shown that TDM is an efficientExpand
Systems oncology: towards patient-specific treatment regimes informed by multiscale mathematical modelling.
TLDR
It is shown that the insights provided by such multiscale modelling approaches can ultimately help in designing optimal patient-specific multi-modality treatment protocols that may increase patients quality of life. Expand
The Pharmacokinetic/Pharmacodynamic Pipeline: Translating Anticancer Drug Pharmacology to the Clinic
TLDR
General conclusions are that greater effort should be made to generate more clinical data that could validate scaled preclinical PB-PK/PD tumor-based models and stimulate a framework for preclinical to clinical translation, and development of predictive PK/PD models will become a standard approach for drug discovery and development. Expand
Network pharmacodynamic models for customized cancer therapy
TLDR
By linking PK models to ePD models, a full spectrum of pharmacological simulation tools is available to design sophisticated multidrug regimens and it is likely that ePD and PK/ePD models will be considered a viable enterprise to customize anticancer drug therapy. Expand
Practical Treatment Guide for Dose Individualisation in Cancer Chemotherapy
TLDR
For drugs such as anticancer agents with a very narrow therapeutic index, every effort should be made to minimise interpatient variability in drug exposure in order to maximise the benefit while keeping the risk of serious adverse effects at an acceptable level. Expand
Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.
TLDR
Considerable effort should be made to better define concentration-effect relationships and to utilise tools such as population PK/PD models and comparative randomised trials of classic dosing versus pharmacokinetically guided adaptive dosing to promote TDM guidelines among the oncological community. Expand
Personalizing oncology treatments by predicting drug efficacy, side‐effects, and improved therapy: mathematics, statistics, and their integration
TLDR
More accurate and versatile personalization tools can be constructed by a new application of the statistical/mathematical nonlinear mixed effects modeling (NLMEM) approach, which until recently has been used only in drug development. Expand
Therapeutic drug monitoring in cancer--are we missing a trick?
TLDR
Applications for TDM during oral targeted therapies may best be reserved for particular situations including lack of therapeutic response, severe or unexpected toxicities, anticipated drug-drug interactions and concerns over adherence treatment. Expand
Optimizing Drug Regimens in Cancer Chemotherapy by an Efficacy-Toxicity Mathematical Model
TLDR
A mathematical model describing the pharmacokinetics of anticancer drugs, antitumor efficacy, and drug toxicity was used to optimize treatment and provided for greater cytoreduction, while limiting the risk of unacceptable toxicity. Expand
Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model
TLDR
A new computational method can serve for tailoring efficacious cytotoxic and supportive treatments, minimising side effects to individual patients. Expand
...
1
2
3
4
5
...